Of money and trust in medical care redux

Mens Sana Monographs

Volumn 10, Issue 1, 2012, Pages 143-149

  Lexchin, Joel ^a  

^a York University   (Canada)

Author keywords

Doctors; Financial conflict of interest; Gifts; Pharmaceutical industry; Promotion

Indexed keywords

EID: 84861326781     PISSN: 09731229     EISSN: 19984014     Source Type: Journal    
DOI: 10.4103/0973-1229.91294     Document Type: Article

References (23)

1. Almashat S, Preston C, Waterman T, Wolfe S. Rapidly increasing criminal and civil monetary penalties against the pharmaceutical industry: 1991 to 2010. Washington D.C.: Public Citizen's Health Research Group; 2010.
2. American Medical Student Association. 2011. AMSA PharmFree Scorecard 2010. Available from: http://www.amsascorecard.org/[Accessed on 12 Dec 2011].
3. Cialdini RB. The science of persuasion. Sci Am 2001;284:76-81.
4. Freshwater DM, Freshwater MF. Failure by deans of academic medical centers to disclose outside income. Arch Intern Med 2011;171:586-7. PMID: 21444851.
5. Fugh-Berman A, McDonald CP, Bell AM, Bethards EC, Scialli AR. Promotional tone in reviews of menopausal hormone therapy after the Women's Health Initiative: An analysis of published articles. PLoS Med 2011;8:e1000425. PMID: 21423581.
6. Gagnon MA, Lexchin J. The cost of pushing pills: A new estimate of pharmaceutical promotion expenditures in the United States. PLoS Med 2008;5:e1. PMID: 18177202.
7. Goozner M. The latest advisory committee stumbles at FDA. GoozNews.com. 5 Dec 2011. Available from: http://gooznews.com/[Accessed on 12 Dec 2011].
8. Harris G. Top psychiatrist didn't report drug makers' pay. New York: New York Times; 2008.
9. Jelinek GA, Brown AFT. A stand against drug company advertising. Emerg Med Australas 2011;23:4-6. PMID: 21284808.
10. Kassirer JP. Medicine's obsession with disclosure of financial conflicts: Fixing the wrong problem. In: Snyder PJ, Mayes LC, Spencer DD, editors. Science and the media: Delgado's brave bulls and the ethics of scientific disclosure p. 79-89). Amsterdam, Boston; London: Academic Press; 2008.
11. Kowalczyk L. Perks policy for doctors challenged: Physician organization wants limits rolled back. Boston: Boston Globe; 2009.
12. Lexchin J. Of money and trust in medical care. Mens Sana Monographs 2007;5:7-10. PMID: 22058612.
13. Lexchin J. Those who have the gold make the evidence: How the pharmaceutical industry biases the outcome of clinical trials of medications. Sci Eng Ethics 2011 [In Press]. PMID: 21327723.
14. Licurse A, Barber E, Joffe S, Gross C. The impact of disclosing financial ties in research and clinical care: A systematic review. Arch Intern Med 2010;170:675-82. PMID: 20421551.
15. Morgan MA, Dana J, Loewenstein G, Zinberg S, Schulkin J. Interactions of doctors with the pharmaceutical industry. J Med Ethics 2006;32:559-63. PMID: 17012493. (Pubitemid 44560466)
16. Moynihan R., Mintzes B. Sex lies and pharmaceuticals: how drug companies plan to profit from female sexual dysfunction. Sydney: Allen & Unwin Pty Ltd; 2010.
17. A noble cause. ABC Radio National. 16 Oct 2011. Available from: http://www.abc.net.au/radionational/programs/backgroundbriefing/a-noble-cause/ 3583670 [Accessed on 12 Dec 2011].
18. Pew Prescription Project. Physician payments sunshine provisions in health care reform. 2011. Available from: http://www.prescriptionproject.org/ tools/sunshine-docs/files/Sunshinefact-sheet-6.07.10.pdf [Accessed on 12 Dec 2011].
19. Ross JP, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofecoxib: A case study of industry documents from rofecoxib litigation. JAMA 2008;299:1800-12. PMID: 18413874. (Pubitemid 351549971)
20. Rutledge P, Crookes D, McKinstry B, Maxwell SR. Do doctors rely on pharmaceutical industry funding to attend conferences and do they perceive that this creates a bias in their drug selection? Results from a questionnaire survey. Pharmacoepidemiol Drug Saf 2003;12:663-7. PMID: 14762982. (Pubitemid 38028780)
21. Silverman E. Pharma free: Oregon docs ban CME funding. Pharmalot. 13 Mar 2008. Available from: http://www.pharmalot.com/2008/03/pharma-free-oregon-docs- ban-cme-funding/[Accessed on 12 Dec 2011].
22. Spurling GK, Mansfield PR, Montgomery BD, Lexchin J, Doust J, Othman N, et al. Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: A systematic review. PLoS Med 2010:7:e1000352. PMID: 20976098.
23. Steinman MA, Shlipak MG, McPhee SJ. Of principles and pens: Attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. Am J Med 2001;110: 551-7. PMID: 11347622.